COMP <GO>
DCOY vs ENLV // EV/EBITDA & P/E VALUATION
Decoy Therapeutics Inc. (NASDAQ) VS. Enlivex Ltd. (NASDAQ) • 15-METRIC TALLY: DCOY 0
— ENLV 3
■ METRIC PARITY
LAST: $1.03 (-3.27%) • MKT CAP: $2.6M
valuation
—
LAST: $1.41 (-20.79%) • MKT CAP: $2.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DCOY VS. ENLV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DCOY | ENLV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -0.60% | -34.40 | ENLV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.7 | 59.5 | -22.80 | ENLV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.6M | $2.7M | -$174.7K | ENLV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DCOY REV | ENLV REV | DCOY GROSS % | ENLV GROSS % | DCOY FCF | ENLV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $35.3M | $42.1M | — | — | -$4.8M | -$10.5M |
| FY 2024 | $16.1M | $44.5M | — | — | -$4.5M | -$13.1M |
| FY 2023 | $36.1M | $82.3M | — | — | -$12.8M | -$23.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DCOY // BETA —
ENLV // BETA —